RecruitingPhase 4NCT07357324

A Clinical Observation Study of a Chinese Patent Medicine Combined With Tamsulosin in Improving Sleep and Nocturia Symptoms After Enucleation of the Prostate


Sponsor

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Enrollment

136 participants

Start Date

Dec 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study will test whether a traditional Chinese medicine called Lingze tablets, when added to the standard drug tamsulosin, can better improve sleep and nighttime urination problems in men after prostate surgery. Who can participate? Men aged 50 years or older who have had transurethral holmium laser enucleation of the prostate (a minimally invasive surgery for enlarged prostate) and continue to have bothersome nighttime urination (at least 2 times per night) and other urinary symptoms may be eligible. Who cannot participate? Men who cannot tolerate the study medications, have severe cancer, serious organ failure, or have conditions that prevent them from understanding or following the study requirements. What will participants do? About 136 participants will be randomly assigned (by chance, like a coin flip) to one of two groups: Group 1: Take tamsulosin sustained-release capsule once daily for 8 weeks Group 2: Take tamsulosin sustained-release capsule once daily PLUS Lingze tablets (4 tablets, three times daily) for 8 weeks Participants will visit the hospital clinic at the start of the study, at 4 weeks, and at 8 weeks for assessments. What will be measured? Researchers will measure: How many times you wake up at night to urinate Overall sleep quality using standard questionnaires Prostate symptom scores and quality of life Urine flow tests (non-invasive) Anxiety levels Any side effects or adverse events from the medications Why is this study important? Many men continue to have nighttime urination and poor sleep even after prostate surgery, which can greatly reduce quality of life. This study will help determine if combining Lingze tablets with standard treatment provides better relief than standard treatment alone. Risks and Benefits: Potential benefits: Improved sleep, fewer nighttime bathroom trips, better urinary symptoms, and enhanced quality of life. Potential risks: Possible side effects include dizziness, headache, nausea, or stomach upset from the medications. All participants will be closely monitored for any problems and can contact the study team 24/7 with concerns. Privacy: All personal and medical information will be kept confidential and used only for research purposes in accordance with hospital and national regulations.


Eligibility

Sex: MALEMin Age: 50 Years

Inclusion Criteria7

  • Male patients aged 50 years or older
  • History of transurethral holmium laser enucleation of the prostate (HoLEP)
  • Nocturia frequency ≥2 times per night
  • Documented bladder outlet obstruction
  • Presence of postoperative urinary incontinence and urgency symptoms
  • Ability to understand study procedures and provide written informed consent
  • Willingness to complete all scheduled follow-up visits and assessments

Exclusion Criteria6

  • Known hypersensitivity or intolerance to tamsulosin hydrochloride, Lingze tablets, or any component of these medications
  • Active malignancy or severe cancer requiring treatment
  • Cognitive impairment, psychiatric disorder, or language barrier that prevents understanding of study requirements or completion of questionnaires
  • Severe multi-organ failure or dysfunction that would interfere with study participation
  • Previous enrollment in conflicting clinical trials within the past 30 days
  • Inability to comply with the medication regimen or study protocol

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTamsulosin Hydrochloride Sustained-Release Capsules

Tamsulosin is an alpha-1 adrenergic receptor antagonist used as standard therapy to relieve lower urinary tract symptoms by relaxing the smooth muscle of the bladder neck and prostate. This study uses 0.2 mg sustained-release capsules administered orally once daily at bedtime for 8 weeks. The medication (National Drug Approval Number: H20000681) is manufactured by Jiangsu Hengrui Medicine Co., Ltd. It is administered to participants in both the control arm (monotherapy) and the experimental arm (combination therapy).

DRUGLingze Tablets

Lingze tablets are a traditional Chinese patent medicine composed of herbal extracts including Rhizoma Alismatis, Poria, Radix Rehmanniae Preparata, Rhizoma Curculiginis, and Herba Epimedii. According to traditional Chinese medicine theory, it tonifies kidney qi, clears dampness and heat, and promotes blood circulation to alleviate urinary symptoms. In this study, it is administered orally at 4 tablets three times daily for 8 weeks, in combination with tamsulosin, to participants in the experimental arm only. The product (National Drug Approval Number: Z20110050) is manufactured by Zhejiang Conba Pharmaceutical Co., Ltd.


Locations(1)

The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine,Zhejiang University

Yiwu, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07357324


Related Trials